METOCLOPRAMIDE HYDROCHLORIDE

Post-LOE

metoclopramide hydrochloride

Pfizer

ANDAORALTABLET, ORALLY DISINTEGRATING

Approved

Aug 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METOCLOPRAMIDE HYDROCHLORIDE (metoclopramide hydrochloride) by Pfizer is gastric, biliary, or pancreatic secretions. Approved for documented gastroesophageal reflux disease (gerd) in adults with. First approved in 2014.

Drug data last refreshed 23h ago

Mechanism of Action

gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of…

Indications (1)

documented gastroesophageal reflux disease (GERD) in adults with

Worked on METOCLOPRAMIDE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.